Your session is about to expire
Invokana vs Glyburide
Introduction
For patients with type 2 diabetes, certain drugs that influence the levels of blood sugar can help in managing symptoms and preventing severe complications. Invokana and Glyburide are two such medications often prescribed for this condition. They each impact different processes in the body, but both aim to control blood glucose levels effectively.
Invokana is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by blocking a protein responsible for reabsorbing glucose into the bloodstream from the kidneys, hence promoting its excretion through urine and reducing overall blood sugar levels.
Glyburide, on the other hand, belongs to a class of drugs known as sulfonylureas; it stimulates the pancreas to produce more insulin – a hormone essential for regulating blood sugar levels. Thus while both these medicines work towards controlling high blood glucose levels seen in diabetics, they do so via distinct mechanisms.
Invokana vs Glyburide Side By Side
| Attribute | Invokana | Glyburide |
|---|---|---|
| Brand Name | Invokana | Glyburide |
| Contraindications | Should not be taken if you are taking other SGLT2 inhibitors. Not recommended for individuals with kidney disease. | Should not be taken if you are taking other sulfonylureas. Not recommended for individuals with kidney disease. |
| Cost | Approximately $4.33 - $10 per day for the generic version | Starting from just under $.02/day up to about $.75/day for the generic version |
| Generic Name | Canagliflozin | Glyburide |
| Most Serious Side Effect | Kidney problems, signs of a urinary tract infection, high potassium level symptoms | Severe allergic reactions, liver issues, jaundice |
| Severe Drug Interactions | Not specified, but caution is advised when taking medications that may interact with SGLT2 inhibitors. | Not specified, but caution is advised when taking medications that may lead to severe hypoglycemia. |
| Typical Dose | 100 mg/day, can be increased to 300 mg/day if needed | 2.5–5 mg/day, may be increased based on response. Maximum daily dose should not exceed 20 mg. |
What is Invokana?
Canagliflozin (the generic name for Invokana) was the first drug of the SGLT2 inhibitors class used to treat type 2 diabetes, which marked a major advancement over the older class of drugs known as sulfonylureas, such as Glyburide. Canagliflozin was first approved by the FDA in 2013. Invokana works by inhibiting sodium-glucose transport proteins that help reabsorb glucose into the blood from kidneys, effectively allowing more sugar to be excreted through urine and lowering blood glucose levels. It is prescribed primarily for adults with type 2 diabetes but can also reduce heart-related issues and kidney disease in these patients.
On the other hand, Glyburide increases insulin production by stimulating beta cells in the pancreas instead of altering kidney function. Consequently, it may lead to hypoglycemia (low blood sugar), a side effect less commonly associated with Invokana due its different mechanism of action.
What conditions is Invokana approved to treat?
Invokana is approved for the treatment of various types of diabetes:
- Type 2 diabetes mellitus in adults as an adjunct to diet and exercise
- To reduce the risk of major cardiovascular events such as heart attack, stroke or death in patients with type 2 diabetes who have known cardiovascular disease
- In combination with metformin and a sulfonylurea (like glyburide) when diet and exercise plus dual therapy does not provide adequate glycemic control.
How does Invokana help with these illnesses?
Invokana helps to manage type 2 diabetes by increasing the amount of glucose excreted in urine. It does this by inhibiting a protein called SGLT2 in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. Glucose is a simple sugar that provides energy to all cells in our body and plays a crucial role in many physiological processes such as growth, metabolism, brain function among others. In individuals with type 2 diabetes, there's an excessive amount of glucose circulating within their bodies due to insulin resistance or lack of sufficient insulin production. Therefore, by preventing glucose reabsorption and encouraging its excretion through urine, Invokana can help lower blood sugar levels effectively aiding patients to manage their condition and keep their blood sugars under control.
Glyburide on the other hand works differently - it stimulates pancreatic beta cells to release more insulin thereby helping reduce high blood sugar levels seen in diabetics.
What is Glyburide?
Glyburide, also known by the brand names Micronase and Diabeta, is a second-generation sulfonylurea that aids in controlling high blood sugar levels in individuals with type 2 diabetes. It works by prompting the pancreas to produce more insulin and helping the body use insulin more efficiently, thereby reducing glucose production and absorption. Glyburide was first approved by the FDA in 1984.
As it operates through stimulating insulin release rather than enhancing excretion of glucose like Invokana (canagliflozin), its side-effect profile differs significantly. Common side effects include hypoglycemia (low blood sugar levels), weight gain, nausea or heartburn - unlike Invokana which can lead to urinary tract infections due to increased glucose excretion via urine.
Importantly, glyburide does not have beneficial cardiovascular outcomes associated with some SGLT-2 inhibitors like Invokana but could be preferred in patients who cannot tolerate such medications or those suffering from renal impairment where SGLT-2 inhibitors are contraindicated.
What conditions is Glyburide approved to treat?
Glyburide, a type of oral medication for diabetes management, is approved by the FDA for:
- Glycemic control in patients with type 2 diabetes mellitus
- Management of gestational diabetes (in some cases), when diet and exercise alone does not result in adequate glycemic control
Remember that all medications should be taken under physician supervision to avoid potential side effects.
How does Glyburide help with these illnesses?
Glyburide, just like Invokana, is a medication used to manage diabetes mellitus type 2. It operates differently though by encouraging the pancreas to secrete more insulin which in turn helps lower blood sugar levels. This action taps into the body's existing insulin production process instead of bypassing it as other drugs do. Glyburide is part of a class of medications known as sulfonylureas and has been utilized for many years in managing this chronic condition. However, because glyburide works by stimulating insulin secretion from pancreatic beta cells, it may be less effective when these cells are significantly damaged or depleted – a situation that can develop over time in patients with long-standing diabetes. In such cases where patients do not respond well to sulfonylureas like glyburide, alternatives such as sodium-glucose co-transporter 2 (SGLT2) inhibitors like Invokana might be considered.
How effective are both Invokana and Glyburide?
Both canagliflozin (Invokana) and glyburide have recognized histories of success in managing symptoms of type 2 diabetes, although they were approved by the FDA decades apart, with glyburide having been used since the early 1980s and Invokana only being introduced in 2013. As they act on different aspects of glucose metabolism, these drugs are often prescribed under various circumstances.
The effectiveness of Invokana and glyburide was directly compared in a double-blind clinical trial in 2014; both drugs were found to be effective at reducing HbA1c levels over a period of 52 weeks. In this study, there wasn't any significant difference between patients receiving Invokana or those receiving glyburide when it came to lowering blood sugar levels. However, weight loss was observed more frequently in the group taking canagliflozin (Invokana), while hypoglycemia occurred more frequently among those on glyburide.
Reviews suggest that Invokana has an advantage when it comes to reducing cardiovascular risk factors due its diuretic effect which helps reduce blood pressure - a common concern for many individuals with type-2 diabetes. It also seems to aid moderate weight loss which is beneficial for overweight diabetic patients.
Glyburide is one of several sulfonylureas available for treating type-2 diabetes and works by stimulating insulin release from beta cells within the pancreas. Sulfonylureas like Glyburide are typically considered as second-line treatment options after metformin therapy fails or if metformin is contraindicated due its renal side effects especially among elderly populations.
Although data confirming its efficacy as stand-alone treatment exists for both medications, certain side-effects such as urinary tract infections with invokana and increased risks for severe hypoglycemia with long-term use makes patient education key when prescribing either medication.
Related trials for invokana and glyburide
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Invokana typically prescribed?
Oral dosages of Invokana usually start at 100 mg/day taken once in the morning before the first meal, but studies have indicated that this dosage is effective for treating type 2 diabetes in most people. If further blood sugar control is needed, the dose may be increased to a maximum of 300 mg/day. On the other hand, Glyburide doses range from 1.25–20 mg/day and are typically divided into one or two doses per day with meals. In either population, dosage adjustments should be made based on individual patient's glycemic response under doctor’s supervision.
At what dose is Glyburide typically prescribed?
Glyburide therapy is typically initiated at a dosage of 2.5–5 mg/day, taken by mouth before breakfast or the first main meal of the day. The dose may be increased in increments of no more than 2.5 mg at weekly intervals based on your body's response and blood glucose levels until an adequate level is achieved to control blood sugar levels. Maximum daily dose should not exceed 20 mg, divided into two doses if it exceeds 10 mg per day, with each dose spaced approximately 12 hours apart. If there is no response to treatment after several weeks at maximum dosage, alternative treatment options may need to be considered.
What are the most common side effects for Invokana?
Potential side effects from Invokana may include:
- Frequent urination
- Thirst or dry mouth due to increased hydration needs
- Yeast infections in both men and women, due to excess sugar in urine
- Nausea and constipation
- Fatigue (general weakness)
- Elevated cholesterol levels
- Weight loss
In comparison, Glyburide can cause these potential side effects:
- Hypoglycemia (low blood sugar), which could lead to symptoms such as sweating, trembling, hunger, confusion or dizziness
- Nausea and heartburn
- Allergic skin reactions like rash or itching -Sensitivity to sunlight resulting in sunburns easily -Dizziness or lightheadedness if stood up quickly.
Are there any potential serious side effects for Invokana?
While both Invokana and Glyburide are effective in managing blood sugar levels, they carry different potential side effects:
Invokana may cause dehydration symptoms such as excessive thirst or urination, dizziness upon standing up, or dry mouth. More serious side effects can include kidney problems (trouble urinating; swelling in legs, ankles or feet), signs of a urinary tract infection (burning sensation when you pee; pain in the lower part of your stomach), high potassium level symptoms like slow heart rate, weak pulse or muscle weakness.
Glyburide on the other hand can cause low blood sugar symptoms including headache, hunger, sweating and irritability. In rare cases it could lead to skin rash with blistering and peeling which is an indication of severe allergic reaction.
Both medications might also result in weight gain. If you experience any of these side effects with either drug consistently despite maintaining proper diet and exercise routines please consult your healthcare provider immediately.
What are the most common side effects for Glyburide?
The medication Glyburide, used in the management of type 2 diabetes, can induce a variety of side effects that patients should be aware of:
- Nausea or heartburn
- Feeling full
- Weight gain
- Dizziness or lightheadedness
- Mild rash or redness on your skin
- Sleep problems (insomnia)
- Sensitivity to sunlight (you may sunburn more easily) It's important to note that while these are common side effects, they are often mild and manageable. However, if you experience symptoms such as confusion, rapid heartbeat, shaking/tremors, sweating excessively - typically signs of low blood sugar - it's crucial to seek immediate medical attention.
Are there any potential serious side effects for Glyburide?
Glyburide has been a trusted treatment for type 2 diabetes for many years, yet it can sometimes lead to serious side effects. These include:
- An allergic reaction with symptoms such as hives, itching, fever or swollen glands
- Difficulty breathing and swelling in the face or throat
- Unusual bleeding or bruising under the skin
- Yellowing of your skin or whites of your eyes (jaundice)
- Severe nausea, vomiting, and abdominal pain which may be indicative of a liver issue
- Confusion or changes in behavior
- Dark urine and light-colored stools
If you experience any severe reactions while taking Glyburide, it's crucial to seek immediate medical attention. Regular monitoring is also essential when managing diabetes effectively with medication.
Contraindications for Invokana and Glyburide?
Both Invokana and Glyburide, like other medications for diabetes, may cause hypoglycemia or low blood sugar in some people. If you notice symptoms such as sudden sweating, shaking, fast heartbeat, hunger, blurred vision, dizziness or tingling hands/feet it could be a sign of low blood sugar. Don't ignore these symptoms; instead seek immediate medical attention.
Neither Invokana nor Glyburide should be taken if you are taking SGLT2 inhibitors (in the case of Invokana) or sulfonylureas (for Glyburide). Always inform your physician which medications you are currently on; it's crucial to maintain an adequate period between stopping one medication and starting another to prevent harmful interactions with either Invokana or Glyburide. Furthermore, both drugs have contraindications with individuals suffering from kidney disease so make sure your doctor is aware of any pre-existing conditions before prescribing.
How much do Invokana and Glyburide cost?
For the brand name versions of these drugs:
- The price of 30 tablets of Invokana (100 mg) can average around $500, which works out to about $16.66/day.
- The price for 60 tablets of Glyburide (5 mg), on the other hand, averages at approximately $70, thus working out to around $1.16/day.
Therefore, if cost is a consideration for you and both medications are equally suitable for your condition, then brand-name Glyburide may be less expensive on a per-day treatment basis than Invokana. However, it's essential to remember that cost should not be the primary factor in determining which medication is right for you.
As for their generic versions:
- Canagliflozin (the generic version of Invokana) comes in packs ranging from 30 tablets upward with approximate costs between $4.33 - $10 per day depending upon dosage and where it is purchased.
- Meanwhile, Generic Glyburide has an even lower daily cost starting from as low as just under $.02 /day up to about $.75/day depending upon location and method of purchase.
Popularity of Invokana and Glyburide
Canagliflozin, marketed under the brand name Invokana, was prescribed to approximately 1.5 million people in the US in 2020. It accounted for just over 15% of prescriptions for SGLT2 inhibitors, a class of medications primarily used to manage type 2 diabetes by preventing the kidneys from reabsorbing glucose back into the blood and instead promoting its excretion through urine. Its use has been generally increasing since it was approved by FDA in March 2013.
On the other hand, Glyburide is an older medication that belongs to sulfonylureas class of drugs which works by stimulating pancreas to release more insulin. In terms of prevalence, glyburide alone was prescribed almost about six times as many times as canagliflozin with approximately nine million prescriptions filled in America during 2020. The usage rate accounts for around one-fifth of all sulfonylurea prescriptions and just below five percent overall diabetic medicine prescriptions.
Conclusion
Both Invokana (canagliflozin) and Glyburide have well-documented history of use in managing type 2 diabetes, with numerous clinical trials indicating their efficacy over placebo treatments. Both drugs work to lower blood sugar levels but do so via different mechanisms: Invokana inhibits sodium-glucose transport proteins which help reabsorb glucose into the bloodstream while Glyburide stimulates insulin release from pancreatic cells.
Invokana is often used as a first-line treatment when diet and exercise alone aren't enough. It can also be combined with other medications such as metformin. On the other hand, glyburide has been around longer and may be a good option for those who cannot tolerate newer medicines or are looking for a more cost-effective alternative since it's available in generic form.
Adjustment periods may apply to both drugs; initial side effects like urinary tract infections (for Invokana) or low blood sugar symptoms (for glyburide) might occur but should lessen over time.
The side effect profile between these two drugs varies—both are generally well-tolerated, but note that Invokana may lead to dehydration and kidney problems while glyburide could cause hypoglycemia. Patients taking either drug must monitor their blood glucose regularly, particularly during initiation of therapy or dosage adjustments, and consult their healthcare provider if they notice significant fluctuations in blood glucose readings.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Akhtar, N. (2013, November). Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug. Current Diabetes Reviews. Bentham Science Publishers Ltd.http://doi.org/10.2174/15733998113096660085
- Loomba-Albrecht, L. A., Glaser, N. S., Styne, D. M., & Bremer, A. A. (2009, April). An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. Clinical Therapeutics. Elsevier BV.http://doi.org/10.1016/j.clinthera.2009.04.003
- Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam Ze Letova, Y., … Yefet, E. (2017, January 11). Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care. American Diabetes Association.http://doi.org/10.2337/dc16-2307
- Aston-Mourney, K., Proietto, J., Morahan, G., & Andrikopoulos, S. (2008, February 2). Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia. Springer Science and Business Media LLC.http://doi.org/10.1007/s00125-008-0930-2
- Davidson, J. A., & Sloan, L. (2016, November 16). Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview. Advances in Therapy. Springer Science and Business Media LLC.http://doi.org/10.1007/s12325-016-0434-2
- Ginier, P., Madan, S., Fajardo, F., & Levin, S. R. (1985, September). Once-daily use of glyburide. The American Journal of Medicine. Elsevier BV.http://doi.org/10.1016/s0002-9343(85)80011-5